MiniMed Group Inc. Common Stock (MMED)

FairStock Score: 36/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach MiniMed as a medical-device business with a real product set—insulin pumps, pens, continuous glucose monitors, supplies, software—and a growing revenue base. Revenue rose from $2.5 billion in FY2024, the year ended 2024-04-26, to $2.7 billion in FY2025, the year ended 2025-04-25, and $3.1 billion in FY2026, the year ended 2026-04-24. That is respectable top-line progress in a chronic-disease market. But Graham would stop at the bottom line: net losses deepened from $112.0 million in FY2024 to $213.0 million in FY2025 to $333.0 million in FY2026. Diluted EPS went from -$0.44 to -$0.84 to -$1.30. In fiscal Q3 2026, the quarter ended 2026-01-23, the company reported revenue of $790.0 million and a net loss of $119.0 million, or -$0.47 per diluted share. The latest filed quarter, fiscal Q1 2027, the quarter ended 2026-07-31, showed revenue of $843.0 million and diluted EPS of $0.00, with net income not available, so one quarter does not prove a turnaround. The balance sheet shows low debt with a debt-to-equity ratio of 0.02, but trailing free cash flow is -$316.0 million, a -6.1% FCF yield, and the Piotroski F-Score is only 1/9. Altman Z-Score of 3.14 is not distressed on that measure, but cash burn matters. At the 2026-10-13 close, FairStock calculations put P/B at 1.43, P/E at -16.43, and FairStock Score at 36/100. The market is paying for a future that has not yet appeared in earnings. A durable moat could emerge from installed pumps, consumables, and software, but today the financial record is that of a growing but unprofitable company. I would want evidence of sustained gross margin, cash generation, and narrower losses before calling this a sound value.

In plain English: MiniMed Group sells diabetes devices such as insulin pumps, pens, glucose monitors, and supplies. Sales are growing, but the company has lost money and used cash in each of the past three fiscal years, so the business looks weak on profits today. At $18.40, the price does not look clearly cheap based on current numbers; it depends on future profits that have not yet shown up.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-07-31) · fiscal Q3 2026 10-Q (period ended 2026-01-23) · fiscal Q2 2026 10-Q (period ended 2025-10-24) · fiscal Q1 2026 10-Q (period ended 2025-07-25) · FY2026 10-K (period ended 2026-04-24) · FY2025 10-K (period ended 2025-04-25) · FY2024 10-K (period ended 2024-04-26)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer